INTERFERON-ALPHA(IFN-ALPHA) PROLONGS SURVIVAL FOR PATIENTS WITH CML IN CHRONIC PHASE - PRELIMINARY-RESULTS OF THE UK MRC RANDOMIZED MULTICENTER TRIAL

Geahča maid

• Progress with interferon in CML--results of the MRC UK CML III study.
  Dahkki: Shepherd, P, et al.
  Almmustuhtton: (1996)
• A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups - Results of MRC CML V and HOVON 20 trials.
  Dahkki: Shepherd, P, et al.
  Almmustuhtton: (2001)
• Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFN-alpha versus chemotherapy: No significant adverse effect of prolonged IFN-alpha administration.
  Dahkki: Shepherd, P, et al.
  Almmustuhtton: (1995)
• The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
  Dahkki: Kunio Hayashi, et al.
  Almmustuhtton: (2021-01-01)
• The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases.
  Dahkki: Bonifazi, F, et al.
  Almmustuhtton: (2001)